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Abstract
Objective: The goal of any topical formulation is efficient transdermal delivery of its 
active components.  However, delivery of compounds can be problematic with 
penetration through tough layers of fibrotic dermal scar tissue. 
Approach: We propose a new approach combining high performance liquid 
chromatography (HPLC) and Raman spectroscopy (RS) using a topical of unknown 
composition against a well-known anti-scar topical (as control). 
Results: Positive detection of compounds within the treatment topical using both 
techniques was validated with mass spectrometry. RS detected conformational 
structural changes; the 1655/1446 cm-1 ratio estimating collagen content significantly 
decreased (p<0.05) over weeks (W) 4, 12, and 16 compared to Day (D) 0. The amide 
I band, known to represent collagen and protein in skin, shifted from 1667 cm-1 to 1656 
cm-1 which may represent a change from β-sheets in elastin to α-helices in collagen.  
Confirmatory elastin immunohistochemistry decreased compared to D0, conversely 
the collagen I/III ratio increased in the same samples by W12 (p<0.05, and p<0.0001 
respectively), in keeping with normal scar formation. OCT attenuation coefficient 
representing collagen deposition was significantly decreased at W4 compared to D0 
and increased at W16 (p<0.05).  
Innovation: This study provides a platform for further research on the simultaneous 
evaluation of the effects of compounds in cutaneous scarring by RS and HPLC, and 
identifies a role for RS in the therapeutic evaluation and theranostic management of 
skin scarring.
Conclusions: RS can provide non-invasive information on the effects of topicals on 
scar pathogenesis and structural composition, validated by other analytical 
techniques.
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Introduction
The goal of any topical formulation should be efficient transdermal delivery of its 
actives in order to address the signs and symptoms of abnormal skin scarring.1  There 
are 3 basic layers that make up skin: the outermost epidermis, the dermis (divided into 
an upper papillary layer and a thicker reticular layer) which extends into the inner 
hypodermis (fatty layer).2 The dermis contains all the connective tissue components 
and provides the tensile strength and elasticity of the skin, which are altered through 
the remodelling process of scarring. 3 Separating the dermis from the epidermis is a 
basement membrane.3 Upon wounding, there is disruption of the layers, resulting in a 
loss of structure, and a replacement with scar tissue.3   As there is no reconstitution 
back to its original state, the resultant scar formed may be  linear, depressed 
(atrophic), contracted or raised (hypertrophic or keloid) manifesting in a range of 
symptoms including erythema, pruritus, and pigmentation; and as such, responsible 
for the significant retail market for anti-scar treatments.4 
The commonly utilised treatments include the use of inert silicone gels, oils and sheets 
shown to provide hydration by occlusion.5 Other widely used topicals claim to provide 
moisturization for symptomatic relief of dryness, for example aloe vera6 and vitamin 
E,7 or scar reduction with improvement in  redness and elasticity, using topicals 
containing compounds with anti-inflammatory properties such as epigallocatechin 
gallate (EGCG),8 and formulas such as MEBO (moist exposure burn ointment) Scar 
ointment originally developed for used during burn treatment.9
Delivery of active compounds, however, can be problematic with penetration of the 
stratum corneum of normal skin let alone through abnormal dermal scars containing 
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excessive fibrous tissue. Current widely used methods for assessment of transdermal 
delivery of active compounds include: the use of high-performance liquid 
chromatography (HPLC) and mass spectrometry (MS). MS is commonly used to 
validate HPLC findings as it provides confirmation of the active ingredient(s),10 and 
LC-MS (liquid chromatography- mass spectrometry)  has even been used to 
validate Fourier transform infra-red (FTIR) spectroscopy analysis of the human skin 
barrier.11
Another useful method for detection of, and assessment of, transdermal delivery of 
active compounds is Raman spectroscopy (RS) which is a non-destructive, vibrational 
spectroscopic technique that is used to probe the molecular changes within biological 
tissue.12 RS is a vibrational spectroscopic method that provides a biomolecular 
fingerprint for macromolecules, which contains both chemical information and physical 
information.  As shown by Mendelsohn’s group when conformational changes occur 
in tissue development, disease, repair, or regeneration, they manifest in the spectra.13  
RS is not only used for assessment of transdermal delivery but in both basic research 
and in the clinical setting, where analysis of normal skin composition has been 
demonstrated, as shown by a recent study14 that used RS to obtain quantitative, non-
invasive spectral data on skin thickness. Successful discrimination between layers of 
the epidermis which is normally affected after formalin-fixation (and is also invasive), 
was evidenced due to the higher spatial resolution of RS (1 µm is typical) than other 
non-invasive techniques such as high frequency ultrasound (HFUS) and optical 
coherence tomography (OCT).14
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Clinical problem addressed
Topical treatments are the mainstay of management options for the prevention and 
symptomatic relief of scars; a high number of which are over-the-counter remedies.  
Despite the abundance of topicals on the market, limited scientific evidence exists for 
their effect. Penetration through tough fibrotic scar tissue remains problematic in the 
assessment of anti-scar topical formulations, and the perceived lack of a robust 
methodology to assess transdermal delivery of their actives presents further difficulties 
in providing objective and quantitative analysis.  We present a combined approach to 
the assessment of transdermal delivery of topicals, whilst synergistically providing 
information on the conformational changes taking place within the dermal scar tissue 
which is corroborated by conventional histological techniques. 
To demonstrate the clinical application of RS in the assessment of skin scarring we 
assess transdermal delivery of a topical (MEBO Scar ointment),9 which has an 
unknown mechanism of action and no proven known ‘actives’.  First, using an ex vivo 
human skin organ culture model, utilising the traditional method of HPLC.15 This 
technique confirmed the presence of two compounds, tyramine, and linoleic acid, and 
their delivery could be evidenced within the different dermal layers; the confirmatory 
presence of these compounds was validated by MS.  Effective transdermal delivery 
was then observed using RS.  To validate these findings, the same techniques were 
applied on in vivo skin samples obtained from a clinical trial with the same topical and 
compared to a positive control, (kelo-cote).16 Kelo-cote was selected, as silicone-
based topicals are most commonly used in clinical practice and their effect shown to 
be positive in skin scarring as evidenced by a Cochrane Review.17  
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We therefore, hypothesised that a combi-approach of techniques, allows for 
successful validation of transdermal delivery of a topical even though the compounds 
within the treatment topical remain unknown, with additional information on 
conformational changes within the scar tissue. Figure 1 demonstrates the 
experimental workflow for this study; Part A represents the ex vivo, and B, the in vivo 
components of the study.
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Materials and Methods
Ex vivo human skin organ culture model
We utilised the culture method previously validated and evidenced by our group.15  
Discarded human skin samples were obtained from patients undergoing routine 
aesthetic surgery such as abdominoplasty, who were consented prior to their 
procedure with ethical approval (16/NW/0736) from the University of Manchester.  All 
tissue was tracked and stored in a human tissue biobank following Human Tissue Act 
(HTA) guidelines. Skin was obtained from six patients; three samples were non-
scarred, i.e. ‘normal’ skin, and three were ‘scarred’ skin samples.  
After trimming the excess hypodermal fat, circular organ culture explants were 
prepared with a 6 mm biopsy punch (Kai Medical, Japan). The biopsies were 
transferred to a 24-well plate containing transwell inserts (Corning©, USA), allowing 
them to be suspended in the culture media whilst keeping the epidermis exposed to 
the air-liquid interphase, for the addition of the treatment. Each biopsy was cultured in 
500 L of Williams E culture media (Gibco™, USA) supplemented with 1% 
penicillin/streptomycin, 1% L-glutamine, 1% none-essential amino acid solution, 1% 
ITS+3, and 10 ng/mL hydrocortisone. The culture medium was changed daily, and the 
biopsies were maintained at 37°C in a humidified incubator with a 5% CO2 
atmosphere. 
Topical formulations
MEBO Scar ointment (Julphar Pharma, UAE), comprising sesame, cactus, and 
beeswax, was originally formulated in China from its derivative MEBOTM (moist 
exposed burn ointment), (Julphar Pharma, UAE).9 MEBO Scar claims to possess at 
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least two compounds, tyramine, and linoleic acid, (unknown actives) which are thought 
to improve skin scarring through an enhanced remodelling process and improved 
microcirculation.9 In this study we aim to demonstrate the presence of these 
compounds through dermal scar tissue using the combined aforementioned 
techniques.  Kelo-cote (Sinclair Pharma, UK), comprising 100% silicone-base was 
used a positive control.
Assessment of transdermal delivery using ex vivo samples
‘Normal’ skin ex vivo organ culture samples were used to assess transdermal delivery 
of tyramine and linoleic acid.  The biopsies were divided into 3 groups (n=9).  The first 
group had 5 µL of the treatment topical applied to the epidermis, the second group 
had 5 µL of the positive control applied, whilst the control group had neither topical 
applied. On days 0, 3, 7, and 10; the biopsies were washed with PBS (Phosphate-
buffered Saline)  and then snap frozen and stored at -80C ready for further analysis. 
HPLC
This was also based on the methodology previously demonstrated by our group.15 
Three samples for each condition (n=9) were used for the ex vivo experiments, and 
n=15 for the in vivo (3 for each time point, day 0, treatment topical at weeks 8, 12 and 
16, and positive control topical at week 12).  An optimised Agilent 1100 system, 
(Agilent Tech, USA)  was utilised, and data analysis performed using ChemStation 
(Agilent Tech, USA) software.  Pure linoleic acid and tyramine (Sigma-Aldrich, UK) 
were tested at different concentrations (100mM, 10mM, 100M, 10M), with a column 
(Sphereclone), (Phenomenex Inc, USA) ideal size of 4.6 x 250mm, to generate 
standard curves for quantification.  The solvent condition was acetonitrile at different 
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concentrations (20%, 40%, 70%, 80%, and 90%) with 1% TFA (trifluoroacetic acid).  
The flow rate was 1ml/min at 10, 50, and 100 L volumes.  Detection of linoleic acid 
tyramine was at 225 nm wavelength, at 6 min and 2 min respectively.
Mass Spectrometry
Skin tissue was weighed to ensure it was less than 25 mg. A total of 9 samples from 
different conditions were used, treatment, control, and day 0 (no treatment). Aliquots  
(1 mL of hexane and isopropranolol, at a ratio of 3:2 was added to each sample), and 
was homogenised in a tissue lyser (Quiagen UK), then centrifuged at 15890 g for 15 
min.  The supernatant was collected for MS. All analysis was conducted on a 
QExactive Plus coupled with an Ultimate 3000 UHPLC (Thermo, UK). The UHPLC 
was equipped with an Accucore Vanquish reverse phase column (C18 -2.1 mm x 100 
mm; 1.5 mm particle size). The solvents employed were (A) water + 0.1% formic acid 
and (B) methanol + 0.1 % formic acid. The flow gradient was programmed to 
equilibrate at 98% A for 2 min followed by a linear gradient to 95% B over 10 min and 
held at 95% B for 2 min before returning to 95% A for 2 min. The flow rate was 
300 mL/min. The column was maintained at 40 °C and the samples chilled in the auto-
sampler at 45 °C. A sample volume of 5 L was injected into the column.  Data 
acquisition was conducted in full MS mode in the scan range of 90-1350 m/z with a 
resolution of 70,000, an AGC target of 3e6 and a maximum integration time of 100 ms. 
The samples were analysed in positive (tyramine) and negative mode (linoleic acid) in 
separate acquisitions.
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Clinical trial for in vivo human skin samples
Forty-five subjects were recruited and followed up over a period of 8 months, in order 
to evaluate the role of Mebo Scar (Julphar Pharma, UAE) in skin scarring.17 Samples 
from twenty of these subjects were used for assessment of transdermal delivery using 
RS.  All subjects signed a written consent form, (UREC ref 16098), in addition to 
verbally consenting at each visit in keeping with the declaration of Helsinki principles.  
Sample size and study power was determined by an independent statistician from the 
University of Manchester, considering all background variables, and samples equally 
distributed with no bias.  Recruitment was via the University volunteer intranet pages.  
All subjects were fit and healthy volunteers, were screened prior to participation, and 
those with any relevant medical history were excluded.  The trial was registered on 
ISRCTN registry (ISRCTN16551998).17
After the screening appointment, all subjects received a 5 mm punch biopsy under 
local anaesthetic, to both upper inner arms, to create a uniform scar.  The subjects 
were then divided into 4 groups, representing a temporal sequential time point, at 4, 
8, 12, and 16 weeks.  The subjects attended fortnightly appointment where non-
invasive measurements (including OCT) were taken.  At the first visit following the 
biopsy they were given both the treatment topical, and the positive control, with 
instructions on how to apply them. The subjects, and the trial clinician were blinded as 
to which arm received treatment or control. At their final appointment (dependent on 
group), the scar was excised via a 6 mm punch biopsy under local anaesthetic and at 
this point the subject exited the study.16  All visits took places at University Hospital of 
South Manchester, part of Manchester University NHS Foundation Trust, 
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(Manchester, UK).  Other outcomes of this study were published in another study by 
our group.16
Raman Spectroscopy
Biopsies were snap frozen and stored at -80 oC before use.  They were sliced into 
cross-sections of 10 m thickness and mounted onto Raman-grade calcium fluoride 
slides (Crystran Ltd, UK). Raman analysis was undertaken using a Renishaw inVia 
confocal Raman microscope (Renishaw Plc., UK) equipped with a 785nm laser. The 
instrument was calibrated using a silicon plate focused under a ×50 objective, where 
a static spectrum centered at 520 cm−1 for 1s at 10% power was collected.
Spectral data were collected using the WiRE 3.4 software (Galactic Industries Corp., 
USA). All spectra were acquired using the laser power adjusted on the sample to ∼28 
mW.  An average of six static spectral point measurements were taken in each layer.  
Data acquisition was optimised for our samples; using 100% power of the laser, with 
ten second exposure time and ten accumulations (total measurement time of 100 s), 
in order to analyse each point with the most optimal signal to noise.  After data 
collection any spurious spikes (cosmic rays) in the spectra, were removed using the 
Cosmic Ray Removal function in WiRE.  Raman spectra were truncated in the 
fingerprint region (750-1800 cm-1), baseline corrected, scaled, and smoothed 
(Savitzky-Golay filter) using MATLAB software version R2019b (The MathWorks Inc., 
USA).   Area under the bands peaking at 1655 and 1446 cm-1 were calculated using 
in house scripts and the ratios 1655/1446 were tested by one-way ANOVA and 
multiple compared using Tukey’s test.
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Histology
Formalin-fixed samples (n=16 for each stain) were sectioned on a microtome into 5 
m slices and placed onto glass slides.  The slides were deparaffinised by xylene and 
rehydrated through grades of alcohol. Picrosirius Red staining was performed using 
Picro Sirius Red stain kit ab150681, (Abcam, USA). The Picrosirius Red staining was 
viewed by an Olympus BX63 microscope (Tokyo, Japan) for polarized images; 
collagen I was shown in red/orange and collagen III was shown in green/yellow. Elastin 
staining required antigen retrieval using 10% v/v citrate buffer, (Sigma Aldrich, 
Germany) for 20 min.  Overnight incubation with 1:600 anti-elastin antibody, ab 23747, 
(Abcam, USA).  Alexa Fluo 488 secondary antibody A-11034 (Thermofisher, 
Germany) was added to the sections and incubated for 40 min.  DAPI, 62248, 
(ThermoFisher, Germany) was used to counterstain. Sections were then dehydrated 
cleaned and mounted. 
For Picrosirius Red, ImageJ was used to process the regions of interest, splitting the 
images into different color channels: red for collagen I quantification and green for 
collagen III. Analysis of elastin used Definiens Tissue Studio (Definiens, Germany) to 
quantify the region of interest. The frequency distribution of the collagen and elastin 
expression data was assessed by the Shapiro-Wilk normality test. All data passed the 
normality test and were evenly distributed. Subsequently, one-way ANOVA with 
repeated measurements was performed for both the collagen and elastin datasets. 
The mean collagen I/III ratio and the mean elastin level of each week were compared 
with the mean values of all other weeks. Differences were considered to be statistically 
significant when p < 0.05.
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Results
HPLC and Mass Spectrometry
Following the methodology described above, the standard concentrations of both 
linoleic acid and tyramine were ascertained.  Linoleic acid was present at ten times 
higher concentration, making it easier to detect; neither compound was present in the 
control topical (Figure 2A). To test the penetration of each compound, samples were 
sectioned longitudinally and correlated with H&E staining to ensure the correct dermal 
layer was identified for HPLC (Figure 2B).  Whilst it is possible to detect linoleic acid 
in Day 0 (normal skin, no treatment) and in the samples which received the positive 
control, it was detected at much higher levels in treatment topical samples, although 
notably this peak was smaller with deeper penetration, where it can be presumed 
linoleic acid was present in much lower quantities.  Tyramine was much more difficult 
to detect and was present in low quantities in all samples.  In Figure 2C the average 
peak area of linoleic acid in the treatment samples is much greater, implying that it 
was easier to detect in in vivo samples.  As with the ex vivo samples, the quantities 
detected were lower with deeper penetration, and the average peak area for tyramine 
was much lower, although still detectable in the day 0 and control samples.  To validate 
the presence of both compounds, MS was used to detect linoleic acid and tyramine in 
treatment samples, the average concentration of both compounds is shown in Figure 
2D.  
Raman spectroscopy
Measuring the spectra of the treatment topical, distinctive peaks were noted at 1042-
1120, 1266-1303, 1439, and 1656 cm-1 (Figure 3A) in the Raman spectra of samples 
treated with the topical, although all these peaks may account for lipid, protein, and 
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nucleic acids vibrations in ‘normal’ skin, (listed in 3B)18 they were of higher attenuation.  
Figures 3C and 3D demonstrate the spectra for ex vivo samples for day 0, the positive 
control, and the treatment topical in the epidermis, and dermis, respectively.  The 
spectra are offset to facilitate visualisation, subtle changes are noted in the spectra of 
dermis and epidermis collected from tissue submitted to treatment and positive control 
compared to day 0.
In Figure 4, the treatment topical skin spectra are represented at different time points, 
in the epidermis and dermis.  The time points represent the length of application of the 
topical; i.e., for 4, 8, 12, or 16 weeks compared to baseline (day 0).  As previously 
described,19 skin structures most relevant to scarring are visible at the amide I, amide 
III, and proline bands.  The amide I band represents collagen I in the dermis at 1665 
cm-1, and at 1654 cm-1 in the epidermis representing the α-helix component of 
keratin.20  The amide III band is broad with a peak at 1246 cm-1 associated with the 
proline-rich  (non-polar) and at 1271 cm-1 proline-poor (polar) regions within 
collagen.20  Another band of note is at 1446 cm-1 which is attributed to CH2 scissoring.21 
Previous studies,21 have demonstrated that the 1655/1446 cm-1 band area ratio is 
correlated to the collagen content.  When applying this to the spectra collected at each 
time point for the dermis in 4B, there is a significant decrease between the collagen 
content at weeks 4, 12, and 16 (p<0.05), compared to day 0 (normal skin collagen 
content); despite the rise in collagen content by week 16, it does not return to normal 
levels.   
Interestingly, at week 16 in the treated group, RS showed a shift of the amide I peak 
from 1667 cm-1 to 1656 cm-1 in the dermis (Figure 5).  This shift in the peak may 
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represent a change in protein conformation, from β-pleated sheets in elastin22 in the 
region of 1665 cm-1 to 1675 cm-1 to a region of 1650 cm-1 to 1656 cm-1 which represents 
-helix components of collagen.22  Changes in the amide I peak representing 
secondary structural changes in protein have been recognised in skin previously: 
comparing normal skin to cancerous skin lesions23 though not in the context of human 
skin scars.  To corroborate these findings, traditional histology stains for collagen and 
elastin were carried out on skin scar samples which had the treatment topical applied 
for 4, 8, and 12 weeks.  The images in the column on the left of Figure 6A represent 
Picro Sirius Red staining, imaged under polarised light.  On day 0, there is an even 
distribution of collagen I and collagen III fibres.  At weeks 4, and 8, there are more of 
the yellowish fibres of collagen III.  At week 12, the distribution to collagen fibres is 
beginning to even out; 6B represents the ratio of collagen I/III fibres: at weeks 4 and 
8, this is significantly less than day 0, at week 12 this ratio was significantly higher than 
day 0 (p<0.0001). The column on the right in 6A is anti-elastin antibody 
immunofluorescence staining.  Even at week 12 there are very few elastin (green) 
fibres visible in the dermis.  Figure 6C demonstrates a significant decrease (p<0.05) 
in elastin levels at week 4 compared to day 0, and despite a rise at week 8, there is a 
significant decrease (p<0.05) also at week 12 compared to day 0.  Whilst the RS 
collagen ratio does not demonstrate an increase to day 0 levels, the decrease in 
elastin and increase collagen over time fits with the process of fibrosis and 
corroborates with the shift in the amide I peak at week 16.  Furthermore, clinical 
correlation using the OCT attenuation coefficient (Figure 6D) when volunteers had 
non-invasive measurements, there was a significant decrease in both treated and 
positive control arms compared to day 0 by week 4, which increased and was 
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significantly greater in the treated arm (compared to the control), at week 16 (p<0.05), 
(Figure 6E) though still not at baseline levels – as demonstrated using RS.  
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Discussion
Our study has demonstrated how HPLC and RS can be used to assess transdermal 
delivery of compounds, penetrating scar tissue even when the precise composition 
and mechanism of action of the topical remains unknown.  Identifying penetration 
within each dermal layer is also possible using HPLC, but relies upon correlation of 
each section with H&E staining or careful tissue dissection.  HPLC also relies on 
ensuring appropriate set up and usage of additional substances (solvents), although 
it has a higher signal sensitivity than RS (where techniques based on resonance or 
surface enhanced Raman scattering (SERS) must be employed to improve signal.24-
25  HPLC also detected the overall concentration of the target compound in the whole 
sample, as it is based on the analysis of extracts; whilst Raman is complementary as 
it allows for the detection of levels of the compounds non-destructively in a spatial 
manner with a pixel resolution of  ~1 µm.  The use of cross-sectional samples whereby, 
under the high magnification of the confocal Raman microscope, dermal layers can 
be identified aids this process.  
The novel finding of conformational changes within the scar tissue over sequential 
time points, could prove to be a major clinical benefit in the assessment of scarring, 
and provide additional objective and quantitative therapeutic assessment of topical 
formulations.  RS requires minimal sample preparation or fixation and is non-
destructive (unlike scanning electron microscopy (SEM), immunohistochemistry (IHC), 
or quantitative polymerase chain reaction (qPCR)), and requires no labelling, unlike 
some of these techniques.  There is no loss of spatial information (as in mass 
spectrometry or qPCR), or sample processing (unlike western blots, qPCR, DNA 
microarrays) which is time consuming. RS is also cost-effective compared to more 
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traditional methods (however, we note that the instrument is costly, but after purchase 
no additional materials/chemicals are required). A combi-approach of HPLC with RS 
to evaluate clinical effects of the topical should therefore prove beneficial.  Validation 
of this model using other techniques such as Fourier transform infrared (FTIR) 
microscopy, optical coherence tomography (OCT), high frequency ultrasound (HFUS), 
and traditional histology may also prove useful. 
There is however, an ever-increasing role of RS in the clinical field, in terms of the 
skin, it has been used to assess functional effects of delivery of sunscreens26 for 
example.  RS has the capability of identifying the unique fingerprint of disease 
pathology, and changes within biomarkers in the skin.23 Indeed, despite the huge 
clinical need for treatment for skin scarring, although there are a number of subjective 
scales for scar assessment3 there is no current objective, and quantitative method for 
scarring classification and corresponding therapeutics. 
 
There are limitations to this study: firstly, the reliance of the ability to section 
longitudinally through each dermal layer and accurately correlate with corresponding 
H&E sections in HPLC.  It is also important to acknowledge that skin explants do not 
have the same permeability, elasticity, movement, and pharmacokinetics as intact 
skin, however our group have previously published work15 (and more recently other 
groups)27-28 demonstrating that it is possible to assess topical penetration on skin 
explants.  The inability to use a true placebo compared to the treatment (since the 
treatment topical has no evidence to prove known actives) is another limitation, 
although in this case we were able to demonstrate how compounds could be identified 
in the absence known proven activity.  Finally, we also acknowledge that the study 
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has been conducted on a limited number of individuals and this to some degree is due 
to the invasive sampling required to obtain tissue for HPLC and RS.
We have attempted to validate our RS results with histology and clinical correlation, 
and although no direct comparisons can be made, we have demonstrated trends 
within the different data sets. Extending the histology time points, and indeed the RS 
analysis beyond weeks 12 and 16 respectively, to evaluate wound healing over a 
longer time period, could provide more information.  RS to our knowledge has not 
been able to differentiate between Collagen I and Collagen III, although previous 
studies have demonstrated a differentiation between types I and IV.19 Collagen 
differentiation has however been demonstrated using FTIR29.  In both of these studies, 
pure collagen was used (not from biological tissue).  
Finally, although we have evidenced the treatment topical within the scarred skin 
samples using RS, many of the compounds naturally exist within skin. The use of 
SERS,30 may help identify peaks not within the normal skin spectra which would aid 
in removing this problem, but this is invasive as metallic nanoparticles need to be 
added into the skin.  
We conclude that using RS, overcomes the difficulties in detecting topical-formulation 
compounds at different depths using HPLC (i.e. the depth of penetration can be 
quantified to ensure uniformity across all sections); and can be optimised to assess 
the transdermal delivery of topicals through human skin scars.  We have also 
demonstrated the potential of RS for simultaneous evaluation of the effect of these 
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compounds; with further evaluation of specific bands which may describe scar 
composition.  
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Innovation
RS overcomes the difficulty in identifying compounds and positive penetration through 
scar tissue, validated by HPLC and MS; we have proved this is possible even when 
the composition of the topical is unknown.  There is a role for RS in the clinical setting, 
where there is a lack of objective, and quantifiable means to assess scarring, and in 
monitoring therapeutic effects on scarring parameters by evaluation of structural 
changes within scar tissue. These findings can be corroborated by traditional 
techniques such as IHC, however RS is advantageous as it is non-destructive, does 
not require fixation or labelling, and easily replicable. 
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Key findings
 A combi-approach of HPLC and RS can be used to assess transdermal 
delivery, even when the precise composition of a topical is unknown
 RS overcomes the difficulty of discriminating between dermal layers using 
HPLC, although HPLC has a higher signal sensitivity
 The novel detection of conformational changes using RS provides a role for its 
use in the clinical setting in the assessment of scarring and monitoring 
therapeutic effects of anti-scar topicals
 This combi-approach can be validated using more traditional techniques; MS 
to confirm the presence of compounds, IHC to confirm structural changes
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Abbreviations and acronyms
FTIR Fourier transform infrared 
H&E haematoxylin and eosin
HFUS high frequency ultrasound
HPLC high performance liquid chromatography
IHC immunohistochemistry
MEBO moist exposure burn ointment
MS mass spectroscopy
OCT optical coherence tomography
qPCR quantitative polymerase chain reaction
RS Raman spectroscopy
SEM scanning electron microscopy
SERS surface enhanced Raman scattering
WiRE Windows-based Raman environment
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Figure Legends
Figure 1 Experimental workflow.  1A describes the ex vivo work which was 
initially carried out.  To validate the ex vivo findings, skin samples from a clinical trial 
using the same topicals (1B) were used to test the same techniques (HPLC, and RS).  
MS was then used to confirm the presence of both compounds which were detected 
in HPLC.  Additional conformational changes demonstrated using RS were validated 
with histology stains for elastin and collagen, and clinically with OCT attenuation 
coefficient.
Figure 2 Comparison of the detected concentrations of tyramine and linoleic 
acid in the topicals, and treated samples via HPLC and MS. 2A demonstrates the 
presence of both compounds in the treatment topical, and neither in the positive 
control.  2B shows the results for HPLC on ex vivo samples (n=9): an average of the 
area under each peak (for linoleic acid and tyramine) was taken to quantify the 
detection of both compounds in each layer.  2C shows the results for HPLC on in vivo 
samples (n=15) using the average area under each peak for both compounds in each 
layer; as with 2B, tyramine is present in much lower quantities.  In 2D the average 
concentration of each compound detected in the skin samples with the treatment 
topical applied (n=9) is shown.  Key: D0 = day 0, normal skin, no treatment, Control = 
samples which received the positive control topical, Treatment = samples which 
received the treatment topical.  E = epidermis, P = Papillary dermis, R = reticular 
dermis. 
Figure 3 RS of the treatment topical compared to the positive control and no 
topical.  3A demonstrates the spectrum of the treatment topical with the key bands of 
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high attenuation highlighted.  3B is a table with the band assignments for the peaks 
present within the treatment topical which may also account for constituents of normal 
skin.  3C shows spectra for the treatment topical against day 0 and the positive control 
in the epidermis.  3D shows spectra for the treatment topical against day 0 and the 
positive control in the dermis.  The spectra in 3C and 3D are offset to facilitate 
visualisation.  There are changes within the bands at 1040-1120 and 1200-1320 cm-1 
which are regions highlighted in the treatment topical in 3A.   
Figure 4 RS of in vivo treated skin scar samples at different time points.
4A: Day 0 (no treatment, normal skin), compared to skin scar samples with the 
treatment topical which had been applied for 4, 8, 12, and 16 weeks in the epidermis.  
4B: Day 0 (no treatment, normal skin), compared to skin scar samples with the 
treatment topical which had been applied for 4, 8, 12, and 16 weeks in the dermis.  In 
4A and 4B the spectra are offset to facilitate visualisation. Turkey’s test was used to 
evaluate the significance of the band area ratio (1655/1446 cm-1) relating to collagen 
content in 4C; distinct letters indicate statistically significant differences between the 
groups (p<0.05), i.e. weeks 4, 12, and 16 were statistically significant compared to day 
0.   
Figure 5 Protein conformational changes identified using RS at week 16 in 
treated samples.  A shift in the amide I peak representing -sheet contribution of 
elastin to -helix component of collagen.  RS therefore detected changes in wound 
healing and remodelling.  
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Figure 6 Assessment of collagen and elastin using histology and clinical 
correlation with OCT.  6A shows the polarised light images the Picrosirius stain for 
collagen on the left, and immunofluorescence stain for elastin on the right at day 0, 
weeks 4, 8, and 12.  On the Picro Sirius stain, collagen I fibres stain red/orange, and 
collagen III yellow/green.  Elastin fibres stain green with nuclei in blue. 6B 
demonstrates the collagen I/III ratio which is significantly decreased at weeks 4 and 8 
and increased at week 12 compared to day 0,*** p <0.0001. 6C demonstrates the 
decrease in elastin at weeks 4 and 12 which was significant compared to day 0, * 
p<0.05.  6D demonstrates use of the OCT device and the image from which the 
attenuation compensation is taken.  The attenuation coefficient represents collagen 
deposition, which is significantly less in both arms compared to day 0 (p=0.031), then 
increases in both arms, with a significant increase in the treatment arm compared to 
the control at week 16 (p=0.047), although it has not quite returned to baseline (day 
0) levels (6E). 
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Figure 1 Experimental workflow.  1A describes the ex vivo work which was initially carried out.  To validate 
the ex vivo findings, skin samples from a clinical trial using the same topicals (1B) were used to test the 
same techniques (HPLC, and RS).  MS was then used to confirm the presence of both compounds which 
were detected in HPLC.  Additional conformational changes demonstrated using RS were validated with 
histology stains for elastin and collagen, and clinically with OCT attenuation coefficient. 
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Figure 2 Comparison of the detected concentrations of tyramine and linoleic acid in the topicals, and treated 
samples via HPLC and MS. 2A demonstrates the presence of both compounds in the treatment topical, and 
neither in the positive control.  2B shows the results for HPLC on ex vivo samples (n=9): an average of the 
area under each peak (for linoleic acid and tyramine) was taken to quantify the detection of both compounds 
in each layer.  2C shows the results for HPLC on in vivo samples (n=15) using the average area under each 
peak for both compounds in each layer; as with 2B, tyramine is present in much lower quantities.  In 2D the 
average concentration of each compound detected in the skin samples with the treatment topical applied 
(n=9) is shown.  Key: D0 = day 0, normal skin, no treatment, Control = samples which received the 
positive control topical, Treatment = samples which received the treatment topical.  E = epidermis, P = 
Papillary dermis, R = reticular dermis. 
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Figure 3 RS of the treatment topical compared to the positive control and no topical.  3A demonstrates the 
spectrum of the treatment topical with the key bands of high attenuation highlighted.  3B is a table with the 
band assignments for the peaks present within the treatment topical which may also account for 
constituents of normal skin.  3C shows spectra for the treatment topical against day 0 and the positive 
control in the epidermis.  3D shows spectra for the treatment topical against day 0 and the positive control 
in the dermis.  The spectra in 3C and 3D are offset to facilitate visualisation.  There are changes within the 
bands at 1040-1120 and 1200-1320 cm-1 which are regions highlighted in the treatment topical in 3A.   
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Figure 4 RS of in vivo treated skin scar samples at different time points. 
4A: Day 0 (no treatment, normal skin), compared to skin scar samples with the treatment topical which had 
been applied for 4, 8, 12, and 16 weeks in the epidermis.  4B: Day 0 (no treatment, normal skin), compared 
to skin scar samples with the treatment topical which had been applied for 4, 8, 12, and 16 weeks in the 
dermis.  In 4A and 4B the spectra are offset to facilitate visualisation. Turkey’s test was used to evaluate the 
significance of the band area ratio (1655/1446 cm-1) relating to collagen content in 4C; distinct letters 
indicate statistically significant differences between the groups (p<0.05), i.e. weeks 4, 12, and 16 were 
statistically significant compared to day 0.   
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Figure 5 Protein conformational changes identified using RS at week 16 in treated samples.  A shift in the 
amide I peak representing -sheet contribution of elastin to -helix component of collagen.  RS therefore 
detected changes in wound healing and remodelling. 
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Figure 6 Assessment of collagen and elastin using histology and clinical correlation with OCT.  6A shows the 
polarised light images the Picrosirius stain for collagen on the left, and immunofluorescence stain for elastin 
on the right at day 0, weeks 4, 8, and 12.  On the Picro Sirius stain, collagen I fibres stain red/orange, and 
collagen III yellow/green.  Elastin fibres stain green with nuclei in blue. 6B demonstrates the collagen I/III 
ratio which is significantly decreased at weeks 4 and 8 and increased at week 12 compared to day 0,*** p 
<0.0001. 6C demonstrates the decrease in elastin at weeks 4 and 12 which was significant compared to day 
0, * p<0.05.  6D demonstrates use of the OCT device and the image from which the attenuation 
compensation is taken.  The attenuation coefficient represents collagen deposition, which is significantly less 
in both arms compared to day 0 (p=0.031), then increases in both arms, with a significant increase in the 
treatment arm compared to the control at week 16 (p=0.047), although it has not quite returned to baseline 
(day 0) levels (6E). 
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